MPR

Tremfya Approved for Children With Plaque Psoriasis, Psoriatic Arthritis

The approval for plaque PsO was based on data from the PROTOSTAR trial, which evaluated guselkumab in participants aged 6 to 17 years with moderate to severe plaque PsO.
MPR

Qivigy Approved for Primary Humoral Immunodeficiency in Adults

Qivigy (immune globulin intravenous, human-kthm) is a ready-to-use, sterile, non-pyrogenic liquid solution of human immune globulin for IV administration.
MPR

Trastuzumab Deruxtecan Superior to T-DM1 in High-Risk HER2+ Early Breast Cancer

The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...
MPR

Mediterranean Diet Tied to Improvement in Psoriasis

HealthDay News — A 16-week Mediterranean diet intervention significantly improves psoriasis severity in patients with mild-to-moderate disease receiving stable topical therapy, according to a study ...
MPR

Drop in Hospital Salaries, Staffing Reported After Private Equity Acquisitions

Private equity hospitals reduced ED and ICU salary expenditures after acquisition relative to control hospitals.
MPR

Sprout Organics Widens Recall of Baby Food Pouches for Possible Lead

HealthDay News — Sprout Organics has widened its recall of 3.5-ounce Sweet Potato, Apple & Spinach pouches because some lots may contain elevated levels of lead. The Food and Drug Administration (FDA) ...
MPR

Acute Cystitis Tied to Higher Risk for Urogenital Cancers

HealthDay News — Acute cystitis may signal the presence of urogenital cancers in middle-aged adults, according to a study published online September 16 in BMJ Public Health.
MPR

Prevention Strategies Developed for Cardiovascular Manifestations of COVID

HealthDay News — Prevention strategies for cardiovascular manifestations of acute and long COVID are discussed in a report published online September 18 in the European Journal of Preventive ...
MPR

Palsonify, an Oral Therapy for Acromegaly, Gets FDA Approval

The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...
MPR

FDA Clears Eyeglass Lenses to Slow Myopia Progression in Children

The Food and Drug Administration (FDA) has cleared the Essilor Stellest eyeglass lenses to slow the progression of myopia, with or without astigmatism, in children aged 6 to 12 years at the initiation ...
MPR

Acupuncture Beneficial for Chronic Low Back Pain in Older Adults

Significantly better change scores seen in Roland-Morris Disability Questionnaire at six and 12 months with acupuncture ...
MPR

FDA Removes REMS for Thyroid Cancer Drug Caprelsa

Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.